NR4A1 and breast cancer: BRCA2pv status was linked to delayed testing and lower CRRM and adjuvant chemotherapy rates; however, in the adjusted analysis, BRCA2pv outcomes were not significantly worse compared to BRCA1pv. Our results highlight the importance of prompt BRCA testing for women with BC, irrespective of age and hormone receptor status, to identify BRCApv carriers and enable timely RRS and targeted systemic treatment [61, 66].